All times are shown in GMT. To see all session details in full, get your copy of the complete event guide here.
7:30 am
Morning Coffee
8:15 am Chair’s Opening Remarks
Navigating Regulatory & Ethical Guidelines, Compliance & Patient Tissue Accessibility
8:30 am Roundtable discussion: Exploring Regulatory Guidelines & Best Practices for Model Developers
Synopsis
- Exploring the current regulatory guidelines in incorporating regulatory body guidelines into models
- Understanding how this applies in the context of genetic medicines
- Sharing best practices of patient input at different stages of development
- Which alternative model is likely to be the next approved regulatory method?
- What techniques are regulators considering accepting (other than animal models) joas the next industry standard
9:00 am Access To Patient-Derived Cancer Models: Data, Services And Collaboration.
Synopsis
- How to search for specific patient-derived cancer models (PDCMs): current PDCM data repositories
- Outline of available PDCM-related services provided by European Research
- Infrastructures for academic and industrial research
- Discussing the potential benefits of collaboration with academics for advanced research on PDCMs
9:30 am Session reserved for
Synopsis
10:00 am Fireside Chat: Food for Thought: What Are the Implications Of Model Characteristics?
Synopsis
Inflamaging: Potential Implications of Gender And Age Of Models Compared To Disease
- How are people modelling the age/sex disparities of disease modalities?
- The affect of immunological age on the immune response and thereby gaining an understanding of altered disease progression.
- Why are age and sex underrepresented in the research/not empirically represented?
- Sharing best practices of successful collaboration between patient groups and industry
- To what extent does age/sex affect the results: the impacts of menopause on BRAF resistance mechanisms in melanoma following BRAF inhibition, compared to men on testosterone replacement therapy?
- How do these factors affect clonal haematopoiesis? What implications does that have for translatability
10:30 am Session reserved for
Synopsis
11:00 am
Morning Networking Break
Bioinformatic Knowledge Is Power: Developments & Novel Techniques
11:40 am Deciphering Distinct Tumour Life Histories In Vivo with Somatic Transgenic Evolving Barcodes & Single-Cell Sequencing
Synopsis
- How can genetic barcodes deconvolute the patterns of progression of different tumour types?
- Detection of Clonal sweeps versus other patterns of evolution
- Could this have the capacity to inform clinical standard-of-care or predict clinical success
- Discussion of future applications of the method
- Lessons learnt from technical challenges (germ line recombination, low barcode recovery issues, and the requirement of computational biology expertise)
12:10 pm Session reserved for
Synopsis
Immuno-Involvement? How Do We Turn The Tide On Tumours
12:25 pm Gamma Delta T-Cell Therapy: Development of ICT01, A First-In- Class, Anti-BTN3A Antibody For Activating Vγ9Vδ2 T Cell–Mediated Antitumor Immune Response
Synopsis
- Preclinical models for the development of monoclonal antibody targeting BTN3A, a membrane receptor with no ortholog in mice
- Biomarker package to support Phase 1 clinical studies with a first-in-class therapeutic activating Vg9Vd2 T cell–mediated antitumor immune response
- How biomarkers allow to define the best combination strategies
12:55 pm T-Cell Therapy: How to Model a Trispecific T-cell Engager For MM: Lessons from ISB
Synopsis
- Discussing the efficacy, safety of T-cell engagers
- Assessing the benefits and restrictions of collecting data in vivo vs in vitro for a T-cell engager
- Overviewing the translational relevance of various datasets
1:25 pm Session reserved for
Synopsis
1:40 pm
Networking Lunch
2:25 pm Roundtable Discussion: Organ-on-a-Chip in IO – Where Are We in Today?
Synopsis
- The potential of creating an autologous environment, conversely limitations of personalisation using organ-on-a-chip
- Can we replicate/recapitulate the TME?
- Understanding the complexity of layering of specific cell lines and components
3:25 pm Panel Discussion: How to Predict Your Immuno-Modulation & Immuno-Stimulatory Response?
Synopsis
The potential of using IO, combinational or cell therapy to dial up another biologic to aid in the anti-tumour response. Could this be the next phase of development for immuno-oncology and what are the potential limitations of this approach? This panel will discuss:
- Methods of stimulating/dialling up a biologic
- Understanding of the differences between alternate types of biologics: Cytokine, Macrophage, NK cell
- What are the benefits of utilising these biologics instead of an ADC/cell-therapy?
- Sharing examples of effective and less effective biologic stimulation
- Drawbacks of specific biologics
- Understanding if this improve the clinical success?
4:05 pm Session reserved for
Synopsis
Next Gen Preclinical Models to Maximise Clinical Success
4:35 pm
Afternoon Refreshments & Networking
5:05 pm Optimising clinical therapeutic window using modelling and simulation, validating with nonclinical translational models and utility in an ongoing clinical study
Synopsis
- An example of a cross-functional collaboration between clinical and non-clinical functions enabling dose and schedule optimisation for clinical testing
- Illustrates the importance of translational understanding in light of increasing probability of successful drug development
- Highly relevant considering recent regulatory moves towards optimisation of clinical dose and schedule.
5:35 pm Understanding Gene Signatures if Macrophage Activation to Access Immunological Memory
Synopsis
- Bone marrow and spleen monocytes represent the main source of Tissue Macrophages in infection and malignancy
- Monocyte derived macrophage activation programmes are plastic and single biomarkers are not adequate to characterise their activation
- Gene signatures enable to understand the activation history of cells and point tophenotypic mosaicism in complex milieus such as tumours